scholarly journals Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques

2017 ◽  
Vol 11 (6) ◽  
pp. e0005637 ◽  
Author(s):  
Rebecca Broeckel ◽  
Julie M. Fox ◽  
Nicole Haese ◽  
Craig N. Kreklywich ◽  
Soila Sukulpovi-Petty ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Chikungunya Virus ◽  
Virus Disease ◽  
Rhesus Macaques ◽  
Human Monoclonal Antibody ◽  
Therapeutic Administration

scholarly journals Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2

2020 ◽  
Author(s):  
Ling Zhu ◽  
Yong-Qiang Deng ◽  
Rong-Rong Zhang ◽  
Zhen Cui ◽  
Chun-Yun Sun ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Membrane Fusion ◽  
Conformational Changes ◽  
Rhesus Macaques ◽  
Human Monoclonal Antibody ◽  
Effective Protection ◽  
Promising Candidate ◽  
Therapeutic Monoclonal Antibody ◽  
Successful Infection ◽  
Receptor Recognition

Abstract Receptor recognition and subsequent membrane fusion are essential for the establishment of successful infection by SARS-CoV-2. Halting these steps can cure COVID-19. Here we have identified and characterized a potent human monoclonal antibody, HB27, that blocks SARS-CoV-2 attachment to its cellular receptor at sub-nM concentrations. Remarkably, HB27 can also prevent SARS-CoV-2 membrane fusion. Consequently, a single dose of HB27 conferred effective protection against SARS-CoV-2 in two established mouse models. Rhesus macaques showed no obvious adverse events when administrated with 10-fold of effective dose of HB27. Cryo-EM studies on complex of SARS-CoV-2 trimeric S with HB27 Fab reveal that three Fab fragments work synergistically to occlude SARS-CoV-2 from binding to ACE2 receptor. Binding of the antibody also restrains any further conformational changes of the RBD, possibly interfering with progression from the prefusion to the postfusion stage. These results suggest that HB27 is a promising candidate for immuno-therapies against COVID-19.

Double Lock of a Potent Human Monoclonal Antibody against SARS-CoV-2

2020 ◽  
Author(s):  
Ling Zhu ◽  
Yong-Qiang Deng ◽  
Rong-Rong Zhang ◽  
Zhen Cui ◽  
Chun-Yun Sun ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Membrane Fusion ◽  
Receptor Binding ◽  
Conformational Changes ◽  
Rhesus Macaques ◽  
Human Monoclonal Antibody ◽  
List Type ◽  
Viral Receptor ◽  
Successful Infection ◽  
Receptor Recognition

SummaryReceptor recognition and subsequent membrane fusion are essential for the establishment of successful infection by SARS-CoV-2. Halting these steps can cure COVID-19. Here we have identified and characterized a potent human monoclonal antibody, HB27, that blocks SARS-CoV-2 attachment to its cellular receptor at sub-nM concentrations. Remarkably, HB27 can also prevent SARS-CoV-2 membrane fusion. Consequently, a single dose of HB27 conferred effective protection against SARS-CoV-2 in two established mouse models. Rhesus macaques showed no obvious adverse events when administrated with 10-fold of effective dose of HB27. Cryo-EM studies on complex of SARS-CoV-2 trimeric S with HB27 Fab reveal that three Fab fragments work synergistically to occlude SARS-CoV-2 from binding to ACE2 receptor. Binding of the antibody also restrains any further conformational changes of the RBD, possibly interfering with progression from the prefusion to the postfusion stage. These results suggest that HB27 is a promising candidate for immuno-therapies against COVID-19.HighlightsSARS-CoV-2 specific antibody, HB27, blocks viral receptor binding and membrane fusionHB27 confers prophylactic and therapeutic protection against SARS-CoV-2 in mice modelsRhesus macaques showed no adverse side effects when administered with HB27Cryo-EM studies suggest that HB27 sterically occludes SARS-CoV-2 from its receptor

COVID-19: Update on Pathogenesis and Treatment Strategies

2020 ◽  
Vol 16 (1) ◽  
pp. 1-5
Author(s):  
Rakesh K. Chauhan ◽  
Pramod K. Sharma ◽  
Shikha Srivastava
Keyword(s):  
Monoclonal Antibody ◽  
Plasma Membrane ◽  
Human Monoclonal Antibody ◽  
Cardiac Injury ◽  
Treatment Strategies ◽  
Severe Pneumonia ◽  
Ground Glass Opacity ◽  
Golgi Membrane ◽  
Virus Particles ◽  
Global Pandemic

COVID-19 (Coronavirus disease) is the most contagious virus, which has been characterized as a global pandemic by WHO. The pathological cycle of COVID-19 virus can be specified as RNAaemia, severe pneumonia, along with the Ground-glass opacity (GGO), and acute cardiac injury. The S protein of Coronavirus has been reported to be involved in the entry of the virus into the host cell, which can be accomplished by direct membrane fusion between the virus and plasma membrane. In the endoplasmic reticulum or Golgi membrane, the newly formed enveloped glycoproteins are introduced. The spread of disease occurs due to contact and droplets unleashed by the vesicles holding the virus particles combined with the plasma membrane to the virus released by the host. The present manuscript describes the pathogenesis of COVID-19 and various treatment strategies that include drugs such as chloroquine and hydroxychloroquine, an anti-malarial drug, antibodies: SARS-CoV-specific human monoclonal antibody CR3022 and plasma treatment facilitate the therapeutic effect.

Sign in / Sign up

Export Citation Format

Share Document